Myovant to receive an upfront payment of US $50 million, is eligible to receive commercial launch, sales-based and other milestones totaling up to US $90.5 million
Aims to increase compliance and improve outcomes for People with Diabetes (PwD)
Infigratinib is not FDA-, Health Canada- or Therapeutics Goods Association-approved for any other indication
Avacc 3 has significant advantages over existing whooping cough vaccines
He will be leading the business, operations, P&L, and growth strategy for StanPlus
Pharma exports in 2021-22 sustain a positive growth despite global trade disruptions
Designed to give instant insights on blood sugar, in-depth nutrition and wellness, this programme provides fitness assessments, personalisation and reports for doctors
Access Healthcare for Medical Products (Access Healthcare) provides pharmaceutical companies with innovative marketing and sales solutions in the MENA (Middle East & North Africa) region
The Phase 3 trial will be conducted under the auspices of the first Regenerative Medicine Advanced Therapy (RMAT) designation approved by the USFDA for an EV therapeutic
Approval for primary and booster immunization is based on efficacy and safety data from Japan and international clinical studies
Subscribe To Our Newsletter & Stay Updated
